Pfizer has agreed to acquire Array BioPharma for a total deal value of US$11.4 B. With the deal, Pfizer gains a range of targeted cancer therapies including a triple combination of Braftovi® (encorafenib), Mektovi® (binimetinib) and Erbitux® (cetuximab) for the treatment of BRAF-mutant metastatic colorectal cancer which showed promise to be the first chemotherapy-free treatment for this disease in Phase III results published in May 2019. Pfizer also gains access to a steady stream of royalty revenue from out-licensed medicines, such as Bayer’s Vitrakvi® (larotrectinib) and Roche’s Ganovo® (danoprevir).